OR WAIT 15 SECS
Anne E. White, president, Lilly Oncology, talks about how the lessons she learned from leading a startup helped her to speed Lilly’s drug development from target identification through successful launch.
A recent roundtable moderated by Rob Jekielek of The Harris Poll gathered five biopharma CEOs to discuss the industry’s shifting reputational landscape in the public eye.
Dr. Husseini Manji, Head of Science for Minds, Johnson & Johnson
Click here to read the articles and download the PDF
Liz Barrett, CEO, UroGen Pharma: A Speciality Calling in Cancer
Register by clicking here
Highlighted Videos
October 26, 2020
Digital engagement is becoming the new normal, but it can inhibit the individual connection that is foundational to building long-term customer relationships. How can reps, brand teams, and medical science liaisons strike the right balance of personal and non-personal engagement? The next generation of AI has an answer, writes Derek Choy.
Anthony Finbow, CEO of Eagle Genomics, talks to Pharm Exec about how adding microbiome-based evidence to disease modeling will enable the life sciences industry to understand the subtleties of how drugs interact with different human ‘host’ environments, unlocking new potential for stratified treatments.
October 23, 2020
Dr. Husseini Manji talks to Pharm Exec about his new role as J&J's Head of Science for Minds and how he hopes to foster new ways to treat dementia and serious mental disorders and provide holistic mental care.
Efforts to address prescription drug pricing have expanded. Rick Kelly reports.
GlobalData releases report on the physician's perspective of telemedicine.
October 22, 2020
Pharma marketers can use their "voice" to increase prominence in advertising.
October 21, 2020
Angus Grant, Ph.D., Chief Business Executive of BeiGene, talks to Pharm Exec about his role and his vision for the company’s programs in oncology and beyond.
October 20, 2020
Lise Stevens explores what difference the ISO IDMP (Identification of Medicinal Products) data standards would have made in a COVID-19 context — in applications ranging from pharmacovigilance adverse event reporting and electronic prescribing to falsified medicines control.
The Medical Affairs Digital Strategy Council's Mary Alice Dwyer and Indegene's Sameer Lal talk to Pharm Exec about how digital solutions can help the Medical Affairs function take a leadership role in ensuring fast, efficient, and meaningful responses to all stakeholders at a time of intense pressure.
